You will be presented with a collection of medical randomized controlled trial (RCT) reports addressing a shared clinical question -- for instance, the efficacy of a medical intervention on a disease or condition. Given the titles and abstracts of these reports, your task is to generate the conclusion of the systematic review article synthesizing the key findings. Your conclusion should be a few sentences long. In your response, include only the conclusion and no other text. The RCT reports are below.



Title 1:
Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy
Abstract 1:
Background : Single small enhancing CT lesions ( SSECTL ) of the brain with or without perifocal oedema are common in patients with symptomatic epilepsy in India . Solitary cysticercus granuloma , a benign form of parenchymal neurocysticercosis , is considered to be the most common aetiology for SSECTL . Definite information is lacking regarding the effectiveness of antiparasitic treatment on resolution of these lesions and on long term seizure recurrence . Objective : To evaluate the response to albendazole treatment in patients who had SSECTL and new onset seizures treated with antiepileptic drugs ( AED ) in a prospect i ve clinical trial . Methods : 43 patients who presented with new onset seizures and were documented to have SSECTL were alternatively allocated to receive albendazole 15 mg/kg/day for 2 weeks or no cysticidal therapy . All patients were treated with AED and followed for at least 6 months for seizure recurrence , and serial CT scans were obtained at 4 weeks , 3 months and at study completion . Results : 28 ( 65 % ) patients were aged 5–25 years and 31 ( 72 % ) presented clinical ly with partial motor seizures with or without generalisation . Most of the SSECTL were ring lesions ( 75 % ) and located in and around the sensory – motor cortex at the gray – white junction ( 65 % ) . In the albendazole group , 56 % of patients compared with 35 % in the control group showed resolution of SSECTL ( p = 0.154 ) at 1 month . 22 of 23 patients ( 95.6 % ) , who received albendazole , compared with 14 of 20 patients ( 70 % ) in the control group , demonstrated radiological resolution on study completion ( p = 0.03 ) . Punctate residual calcification and seizure recurrence were observed in four patients ( 9.3 % ) in the control group and in three ( 7 % ) patients in the albendazole group ( p = 0.47 ) . Conclusions : In patients presenting with seizures due to single viable parenchymal neurocysticercosis , albendazole hastens the resolution of SSECTL if treatment is given in the early phase of the illness


Title 2:
Short regimen of praziquantel in the treatment of single brain enhancing lesions
Abstract 2:
Twenty-six patients with single enhancing brain lesion ( SEL ) were openly assigned to receive single-day praziquantel therapy ( n=14 ) , or not ( n=12 ) . From 14 treated patients , complete resolution was found in 11 , partial resolution in two , and the remaining case was later diagnosed as an arteriovenous malformation . Side effects presented in only one patient and remitted in the same day with symptomatic treatment . Conversely , the lesions persisted unchanged in six of 12 patients in the non-treatment group . Untreated patients with persisting lesions were prescribed praziquantel treatment . After this , SELs disappeared in three cases , other diagnoses ( brain tuberculoma and arteriovenous malformation ) were made in two , and one was not evaluated . When analyzed in regard to the baseline serology , resolution of lesions on computed tomography was found in 13 ( complete=12 , partial=1 ) of 14 seropositive patients , whereas it only happened in six ( complete=5 , partial=1 ) of 12 seronegative patients . Serological screening defines a subset of SEL patients with good prognosis . If antiparasitic therapy is to be used in patients with SEL , and we can not find a strong argument against it , single-day praziquantel is the regimen of choice based on duration , costs , and minimal side effects


Title 3:
Randomized controlled trial of albendazole in new onset epilepsy and MRI confirmed solitary cerebral cysticercal lesion: Effect on long-term seizure outcome
Abstract 3:
No trials to date have focused on long-term seizure outcome in solitary cerebral cysticercal lesion ( SCCL ) , which is believed to produce a relatively benign form of epilepsy . This is a prospect i ve r and omized controlled study to evaluate the effect of Albendazole on long-term seizure outcome in patients with MRI-confirmed solitary cerebral cysticercal lesion ( SCCL ) . One hundred and twenty-three patients with new-onset seizures and SCCL on contrast MRI were r and omized to treatment with albendazole  and followed for up to five years with serial MRI and clinical evaluation . At final analysis 103 patients ( M-54 , F-49 ) with a mean age of 18.6+/-10.7 years and follow-up period more than 12 months were included . The mean follow-up duration was 31.4+/-14.8 months ( 12 - 64 ) . At one month follow-up more patients receiving albendazole were seizure-free ( 62 % versus 49 % for controls ) . Subsequently there was no significant difference in overall seizure outcome between the two groups . There was no correlation between seizure semiology , albendazole therapy and long-term seizure outcome . Baseline MRI showed active lesions in all ; 23 % remained active at 12 months with no difference between the albendazole and control groups . Patients whose lesions resolved at 12 months showed better seizure outcome . Reduction in mean cyst area was greater in the albendazole group as compared to the controls and the difference at six months was significant ( p<0.05 ) . At three months follow-up perilesional edema also resolved faster in albendazole group ( p<0.05 ) . Thus , albendazole did not alter the long-term seizure outcome in patients with SCCL and epilepsy . However , albendazole hastened resolution of SCCL on MRI , but interestingly 23 % of lesions were still active 12 months after treatment


Title 4:
Albendazole therapy for neurocysticercosis
Abstract 4:
Objectiue To compare the effectiveness of two regimens of albendazole therapy for neurocysticercosis . Design R and omized , double-blind clinical trial . Setting s Patients admitted to neurologic wards in Lima , Peru . Patients Adult patients with active neurocysticercosis demonstrated by CT and Western blot ( immunoblot ) . Intervention One week ( n = 25 ) versus 2 weeks ( n = 25 ) of albendazole therapy . Measurements Decrease in the number of cysts on CT . Results Effectiveness of albendazole  was 78 % , with no difference between the groups when compared 3 months after therapy . Complete cure was obtained in only 38 % of patients . Patients with more than 20 cysts had poorer responses to therapy . The clinical course and EEG evolution improved in most patients . Side effects were present in 38 % of patients , mainly mild , transient gastrointestinal symptoms . Therapy was also associated with exacerbation of neurologic symptoms . Two patients died in the first year after therapy , both because of aggregated infections of ventricle-peritoneal shunts . One-year follow-up CT showed lesions in three of 10 patients presumed to be cured 3 months after therapy . Conclusions Extension of albendazole therapy for more than 7 days adds no benefits for the patients


Title 5:
Neurocysticercosis: treatment with albendazole and dextrochloropheniramine (preliminary report).
Abstract 5:
KEY WORDS : Neurocysticercosis : Albendazole ; Dextrochloropheniramine ; Treatment . The clinical variability of neurocysticercosis is due to a series of factors such as number , location , form , dimensions and stage of development of the parasite , the nature of its action on the organism and the individual immunological response of the hosu.4,6 . Thus , diagnosis is very difficult , especially in not highly endemic areas or in regions were laboratory support is lacking . Another important feature to be considered in the approach to neurocysticercosis is the lack of an alternative program of antiparasitic treatment . The high coast of treatment with praziquantel and the side effects ' of
In the natural history of neurocysticercosis , the following stages of evolution of parenchymal larval cysts can be observed on neuroimaging : viable cyst , granulomatous cysticercosis and disappearance of cyst with or without residual calcification.2 In the viable cyst stage , the cyst wall is not visible on imaging and the cyst demonstrates little or no perilesional oedema .
Ring-like or nodular areas of enhancement with prominent perilesional oedema mark the phase of granulomatous cysticercosis .
The image shown here demonstrates the granulomatous cysticercosis as a ring-enhancing lesion with scolex and peri-lesional oedema .
Ultimately , the remnant of the cyst is either not visible on the imaging or observed as calcified lesion(s ) .
A single day course of praziquantel has also been employed.7 Surgery is usually reserved for extraparenchymal neurocysticercosis such as an intraventricular cyst , spinal cysticercosis causing spinal cord compression , for hydrocephalus , or for ophthalmic cysticercosis.8 In general , the seizure outcome in solitary cerebral cysticercosis is good in view of the symptomatic nature of the seizure .